Immunai Announces A $215M Series B As Its ‘Immune Cell Atlas’ Matures

Company

About

The company that set out to create an atlas of the human immune system in 2018 had raised about $80 million by February 2021. On Wednesday, the company announced another significantly larger round: a $215 million series B. Solomon also says the company is working to publish a paper showing it can identify specific gene targets that tell whether a patient will respond to certain therapies. In the meantime, Solomon says, the company has been able to move from simply showing correlative data to causative data. “Probably a year ago we were showing strong correlative data – that certain insights we have can explain relationships between certain genes and cells,” he says. But the company has also diversified the types of biological data it’s collecting, analyzing and managing through two major acquisitions this year. Immunai claims this dataset, called the Annotated Multi-omic Immune Cell Atlas, AMICA, is the largest in the world. Let’s be clear: Immunai is far from the only company looking to harness cell-level data, and put it into action.